"Prototype Drug Uses Novel Mechanism To Treat Lung Cancers"
Cells are constantly turning proteins on and off via molecular switches-phosphate molecules-that have become common drug targets. Researchers collaborated to screen a series of drug-like molecules for their ability to reactivate PP2A in lung cancer cells and prevent lung cancer tumors in mice. The prototype drug molecules were created from FDA-approved medications by Michael Ohlmeyer, PhD, an associate professor of pharmacological sciences at the Icahn School of Medicine at Mount Sinai.
- Michael Ohlmeyer, PhD, Associate Professor of Pharmacological Sciences at the Icahn School of Medicine at Mount Sinai
Learn more
Mount Sinai Study Advances Understanding of Personalized Vaccines for Bladder Cancer
May 12, 2025 View All Press Releases
Mount Sinai Researchers Discover How Melanoma May Spread to the Brain
Apr 30, 2025 View All Press Releases
Mount Sinai Showcases Innovative Cancer Research at 2025 AACR Annual Meeting in Chicago
Apr 24, 2025 View All Press Releases
Mount Sinai Leads Phase 3 Trial in Myelofibrosis Treatment
Mar 19, 2025 View All Press Releases
Mount Sinai Highlights Key Updates and Trends for Multiple Myeloma Awareness Month 2025
Mar 03, 2025 View All Press Releases
Mount Sinai Researchers Discover Why Some Colon Cancers Resist Treatment
Feb 12, 2025 View All Press Releases